Skip to main content

Nebreda: "Our advantage is that p38 inhibitors are now available"

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

TVE reports on the recent study on colorectal cancer published in Cancer Cell by Angel R. Nebreda, ICREA and IRB researcher, and BBVA Foundation Cancer Research Professor. Broadcasted in various news slots over the weekend, coinciding with the Intenational Colon Cancer Day, the video describes the identification of the protein p38 as a key regulator of colon cancer progression.

 

 

Watch this video in TVE

 

Related news

27 March 2014

Researchers at IRB discover a key regulator of colon cancer

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).